CMF

Discussion in 'Synthes' started by Anonymous, Oct 14, 2014 at 8:48 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    anyone know how much more we do in sales than the other cmf companies? wondering how close behind us they are and how long til we lose our #1 spot. those looking to jump ship... stryker or biomet and why?
     

  2. Anonymous

    Anonymous Guest

    Well, how much do you do in sales? And it's a rhetorical question anyway, latest market research shows Stryker surpassed you in market share. Better jump ship now...
     
  3. Anonymous

    Anonymous Guest

    Stryker is investing in its people and CMF. Synthes, well JnJ, could not care less about CMF.
     
  4. Anonymous

    Anonymous Guest

    What market research is that?
     
  5. Anonymous

    Anonymous Guest

    smoke another one . . .
     
  6. Anonymous

    Anonymous Guest

    Sorry, denial doesn't make it untrue. Your CMF division is a shadow of its former self. It's really fascinating as a corporate case study.
     
  7. Anonymous

    Anonymous Guest

    Market research that stryker management team presents to their reps. Synthes CMF is the market leader in the US and is light years ahead of Stryker over seas where SYK has less than 1 percent market share. The CMF segment is expected to grow at 1 percent in the US and 15 percent over seas which will allow Synthes to continue its dominance within the market place. Synthes currently dominates in almost every major market within the U.S.
     
  8. Anonymous

    Anonymous Guest

    Patently false, total propaganda presented here. Nobody really knows how a tiny segment like CMF is going to perform. 1% growth? That's really putting your balls out there. Why not just say the market is flat? As far as overseas,(by the way over seas is one word) there is no data and no one with a brain merges all overseas markets into one category. By the way Stryker is extremely well established across Asia and Latin America including CMF so I would check your sources before spouting off next time.
     
  9. Anonymous

    Anonymous Guest

    the data presented is fact, well documented, while your claims are wishful thinking. U.S. growth will continue in the flat to 1% range (cmf segmant).The cmf market worldwide is not a focus of industry players hence the lack of innovation. If you are comparing apples to apple Synthes is in a far better position than Stryker, maybe this will change but highly unlikely.
     
  10. Anonymous

    Anonymous Guest

    well documented where exactly? procedurally the market might not be growing drastically but the market is still expanding with innovation (eg: PSP for mandible)
     
  11. Anonymous

    Anonymous Guest

    If Synthes is so well positioned for growth, why is it merging CMF into trauma and basically dissolving the division and its management? The real truth is the global CMF market is no more than a rounding error which is why it doesn't get mentioned by the analysts when they handicap the industry. CMF reps can no longer live under the belly of their trauma franchise player colleagues and collect easy money. A new day is here - eat what you kill, every man for himself and all that sort of stuff……
     
  12. Anonymous

    Anonymous Guest

    Hah, notice how the Synthes loyalist mouth breathers fail to come to CMF's defense when you start to talk about the dissolution of the business unit into trauma.

    Yes, the CMF market is small. Anyone with half a brain knows it is a niche market segment in the rigid fixation world. It will never, by simple sheer volume, be a major trauma segment- with any company, let alone Synthes. That companies like KLS exist only to cater to CMF is a folly on their part. Unless you have the multidivisional muscle of a large and diverse orthopedic or trauma company raking in billions to justify or warrant CMF R and D, all the small CMF-only players stand to lose out in the long run.

    Unfortunately for Synthes, JnJ no longer sees value in having an independent CMF sales force. Stryker still does. At the end of the day, Stryker will be the place to work if you want to be a CMF rep and have a better earning potential. Spout all the international growth and market speak all you want, but when it comes down to being a well compensated US market CMF rep, Synthes is no longer the place to work. The truth hurts!
     
  13. Anonymous

    Anonymous Guest

    The top 10 Synthes reps make more $ vs. the top 10 stryker reps at CMF.
     
  14. Anonymous

    Anonymous Guest

    True. But that's only because those specific reps have been in their territories longer. Synthes HAD a reputation as being a place that very few ever left. JnJ is killing that and EVERYONE is looking to leave. Small to big and everyone in between knows this ship be sinking...
     
  15. Anonymous

    Anonymous Guest

    Synthes and Stryker reps actually have a lot in common now. They are both leaving in a hurry to go to biomet!
     
  16. Anonymous

    Anonymous Guest

    Simply not true. Please cite territories if you are going to make a bold (albeit decidedly false) claim like this.
     
  17. Anonymous

    Anonymous Guest

    What kind of deal did Bill Elam get with Biomet? Is he safe from J&J pursuit of his non-compete or are they still harassing him? Did he take a lot of business from DePuy Synthes? Is Biomet willing to make more deals like the one they offered Bill? Many folks like me looking for a way out of here are looking for some answers.
     
  18. Anonymous

    Anonymous Guest

    I'd like to know as well. The good times are long over and leadership is non-existent
     
  19. Anonymous

    Anonymous Guest

    JnJ flexed irs muscle and enforced the non-compete. He had flipped some biz but not a lot. UC, the biggest acct, is still using Synthes and said they won't switch. It will be interesting to see how it plays out over time.
     
  20. Anonymous

    Anonymous Guest

    He is making more and working less and doesn't have to deal with the BS. He will be on the shelf at UC In the new year.